Sign In
Buy CAPR
$3.85
-0.240 (-5.87%)
At Close: Aug 10, 2026
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options
FDA panel votes against Capricor's Duchenne heart disease therapy
05:13pm, Wednesday, 29'th Jul 2026
The U.S. FDA's panel of independent advisers on Wednesday voted against the benefits of Capricor Therapeutics' cell therapy, deramiocel, for treating cardiomyopathy in Duchenne muscular dystroph
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy
10:05am, Wednesday, 29'th Jul 2026
--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Pri
CAPR INVESTIGATION: Capricor Therapeutics Investors Should Contact Block & Leviton About Recovering Their Losses
07:45am, Wednesday, 29'th Jul 2026
Boston, Massachusetts--(Newsfile Corp. - July 29, 2026) - Block & Leviton is investigating Capricor Therapeutics (NASDAQ: CAPR) for potential securities law violations. Investors who have lost money i
Ally Bridge Group NY LLC Takes $3.46 Million Position in Capricor Therapeutics, Inc. $CAPR
04:48am, Wednesday, 29'th Jul 2026
Ally Bridge Group NY LLC purchased a new position in shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) during the first quarter, according to the company in its most recent filing with the Securiti
ADAR1 Capital Management LLC Buys Shares of 90,593 Capricor Therapeutics, Inc. $CAPR
04:09am, Wednesday, 29'th Jul 2026
ADAR1 Capital Management LLC purchased a new position in Capricor Therapeutics, Inc. (NASDAQ: CAPR) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange
CAPR INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
08:00pm, Tuesday, 28'th Jul 2026
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CA
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Capricor Therapeuti
Law Offices of Howard G. Smith announces an investigation on behalf of Capricor Therapeutics, Inc. (âCapricorâ or the âCompanyâ) (NASDAQ: [url="]CAPR[/u
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) investors concer
Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation -- CAPR
09:00pm, Monday, 27'th Jul 2026
Why:Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeut
Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CAPR
08:36pm, Monday, 27'th Jul 2026
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics, Inc. (N
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors con
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
01:58pm, Monday, 27'th Jul 2026
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers a
CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC
01:53pm, Monday, 27'th Jul 2026
ATLANTA, July 27, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securiti
